Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives $17.00 Consensus Price Target from Brokerages

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $17.00.

A number of research analysts have recently commented on SENS shares. Weiss Ratings downgraded shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. HC Wainwright dropped their price objective on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Stifel Nicolaus dropped their price objective on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Monday, May 11th.

Senseonics Holdings, Inc. Common Stock Trading Up 6.1%

Shares of SENS stock opened at $5.72 on Tuesday. The company has a 50-day moving average price of $6.42. Senseonics Holdings, Inc. Common Stock has a twelve month low of $4.79 and a twelve month high of $12.58. The firm has a market cap of $239.10 million, a P/E ratio of -2.86 and a beta of 1.04. The company has a quick ratio of 3.19, a current ratio of 3.51 and a debt-to-equity ratio of 1.05.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative net margin of 213.87% and a negative return on equity of 129.97%. The company had revenue of $11.71 million for the quarter. As a group, research analysts predict that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current year.

Insider Transactions at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 22,686 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average price of $5.56 per share, with a total value of $126,134.16. Following the transaction, the director owned 144,635 shares in the company, valued at $804,170.60. This trade represents a 18.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Senseonics Holdings, Inc. Common Stock

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter worth approximately $68,000. GSK plc acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. Townsend Asset Management Corp NC ADV acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. Cetera Investment Advisers acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter worth approximately $85,000. Finally, Sanctuary Advisors LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $71,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.